What is the first-line treatment for H. pylori (Helicobacter pylori) gastritis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

First-Line Treatment for H. pylori Gastritis

Bismuth quadruple therapy for 14 days is the recommended first-line treatment for H. pylori gastritis, consisting of a PPI twice daily, bismuth subsalicylate, metronidazole, and tetracycline. 1, 2, 3

Primary Treatment Recommendation

The American Gastroenterological Association and American College of Gastroenterology strongly recommend bismuth quadruple therapy as the preferred first-line regimen due to increasing global clarithromycin resistance, which now exceeds 15-20% in most regions of North America and Europe. 1, 2, 3

Specific regimen components: 1, 2

  • PPI (e.g., omeprazole, lansoprazole) 20-40 mg twice daily
  • Bismuth subsalicylate 525 mg four times daily
  • Metronidazole 500 mg three to four times daily
  • Tetracycline 500 mg four times daily
  • Duration: 14 days (preferred over 10 days to maximize eradication rates >80-90%)

Why Bismuth Quadruple Therapy is Preferred

Bismuth quadruple therapy achieves eradication rates of 80-90% even against metronidazole-resistant strains because bacterial resistance to bismuth is extremely rare. 1, 3 This regimen uses antibiotics from the WHO "Access group" (tetracycline and metronidazole) rather than the "Watch group" (clarithromycin, levofloxacin), making it preferable from an antimicrobial stewardship perspective. 1

The critical advantage is that clarithromycin resistance has increased globally from 9% in 1998 to 17.6% in 2008-2009, and now exceeds 20% in most of North America and Europe, causing standard triple therapy eradication rates to drop to approximately 20% with resistant strains compared to 90% with susceptible strains. 1, 2

Alternative First-Line Option (When Bismuth is Unavailable)

Concomitant non-bismuth quadruple therapy for 14 days: 1, 2

  • PPI twice daily
  • Amoxicillin 1000 mg twice daily 4
  • Clarithromycin 500 mg twice daily
  • Metronidazole 500 mg twice daily

This regimen administers all antibiotics simultaneously (not sequentially) to prevent resistance development during treatment. 1

When Triple Therapy May Still Be Considered

Only in areas with documented low clarithromycin resistance (<15%): 1, 2, 3

  • PPI twice daily
  • Clarithromycin 500 mg twice daily 5
  • Amoxicillin 1000 mg twice daily 4, 5, 4
  • Duration: 14 days

Critical caveat: Never assume low clarithromycin resistance without local surveillance data—most regions now have high resistance rates, and standard triple therapy should be abandoned when regional resistance exceeds 15-20%. 1, 2

Optimizing Treatment Success

High-dose PPI dosing is mandatory: Use twice-daily dosing (not once daily) to maximize gastric pH elevation and enhance antibiotic activity, which increases eradication efficacy by 6-10%. 1, 2, 3

Treatment duration: Extending from 7 to 14 days improves eradication success by approximately 5%. 1, 2, 3

Timing: Administer all medications at the start of meals to minimize gastrointestinal intolerance. 4

Special Populations

Penicillin allergy: In patients allergic to penicillin, bismuth quadruple therapy (PPI-bismuth-tetracycline-metronidazole) is the preferred first-line option, achieving 74-75% eradication rates with excellent compliance and tolerability. 6

Clarithromycin-intolerant or resistant patients: Use dual therapy with PPI and amoxicillin (lansoprazole 30 mg three times daily + amoxicillin 1000 mg three times daily for 14 days) as indicated by FDA labeling. 5, 4

Common Pitfalls to Avoid

Never repeat clarithromycin if the patient has prior macrolide exposure for any indication, as cross-resistance is universal within the macrolide family. 1, 2

Avoid standard-dose PPI once daily—this is inadequate and significantly reduces treatment efficacy. 1, 2

Do not use levofloxacin empirically as first-line therapy due to rapidly rising fluoroquinolone resistance rates and FDA warnings about serious side effects. 1

Never use sequential therapy (antibiotics given in sequence rather than simultaneously), as this promotes resistance development during treatment. 1

Verification of Eradication

Confirm eradication with urea breath test or monoclonal stool antigen test at least 4 weeks after completion of therapy and at least 2 weeks after PPI discontinuation. 1, 2, 3 Never use serology to confirm eradication, as antibodies persist long after successful treatment. 2

Managing Side Effects

Diarrhea occurs in 21-41% of patients during the first week due to disruption of normal gut microbiota. 1 Consider adjunctive probiotics to reduce antibiotic-associated diarrhea and improve compliance, though evidence for increased eradication rates is limited. 1, 2

References

Guideline

Helicobacter Pylori Infection Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Helicobacter pylori Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment for Helicobacter pylori Infection

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.